A recent study has shown promising results for patients with FLT3-mutated acute myeloid leukemia. The phase 1/2 study focused on the use of azacitidine, venetoclax, and gilteritinib in treatment, and found that this combination led to high rates of complete response and complete response with incomplete hematologic recovery.
This is significant news for patients with this type of leukemia, as complete response is a key indicator of treatment success. The study’s findings suggest that this combination therapy could be an effective option for patients with FLT3-mutated acute myeloid leukemia.
The results of this study are encouraging and may lead to advancements in treatment options for patients with this type of leukemia. Further research and clinical trials may help to confirm these findings and expand the use of this combination therapy.
